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BACKGROUND:Therapies targeted towards the tumour vasculature can be exploited for the purpose of improving the systemic delivery
of oncolytic viruses to tumours. Photodynamic therapy (PDT) is a clinically approved treatment for cancer that is known to induce
potent effects on tumour vasculature. In this study, we examined the activity of PDT in combination with oncolytic vaccinia virus
(OVV) against primary and metastatic tumours in mice.
METHODS: The effect of 2-[1-hexyloxyethyl-]-2-devinyl pyropheophorbide-a (HPPH)-sensitised-PDT on the efficacy of oncolytic
virotherapy was investigated against subcutaneously implanted syngeneic murine NXS2 neuroblastoma and human FaDu head and
neck squamous cell carcinoma xenografts in nude mice. Treatment efficacy was evaluated by monitoring tumour growth and survival.
The effects of combination treatment on vascular function were examined using magnetic resonance imaging (MRI) and
immunohistochemistry, whereas viral replication in tumour cells was analysed by a standard plaque assay. Normal tissue phototoxicity
following PDT-OV treatment was studied using the mouse foot response assay.
RESULTS: Combination of PDT with OVV resulted in inhibition of primary and metastatic tumour growth compared with either
monotherapy. PDT-induced vascular disruption resulted in higher intratumoural viral titres compared with the untreated tumours.
Five days after delivery of OVV, there was a loss of blood flow to the interior of tumour that was associated with infiltration of
neutrophils. Administration of OVV did not result in any additional photodynamic damage to normal mouse foot tissue.
CONCLUSION: These results provide evidence into the usefulness of PDT as a means of enhancing intratumoural replication and
therapeutic efficacy of OV.
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Oncolytic viruses replicate in and destroy cancer cells selectively
(Guo et al, 2008; Kirn and Thorne, 2009). Clinical trials performed
over the last decade to evaluate the activity of oncolytic viruses
have utilised local (e.g., intratumoural) or regional (e.g., intra-
cavitary or intra-arterial) routes of delivery (Hu et al, 2006; Small
et al, 2006; Liu et al, 2008). However, effective treatment of
invasive and metastatic cancer is likely to require systemic
administration of the virus. Poxviruses are characterised by
their ability to travel systemically through the blood (Thorne
et al, 2007; Kirn et al, 2008) because the extracellular enveloped
vaccinia virus shrouds itself in a host cell-derived envelope that
contains several host complement control proteins and few
exposed viral proteins making it resistant to neutralisation by
complement (Vanderplasschen et al, 1998; Bell et al, 2004).
Engineered oncolytic vaccinia viruses (OVVs) have demonstrated
promising results in the treatment of cancer in preclinical models
and early clinical trials (Park et al, 2008; Kirn and Thorne, 2009),
and systemic virus spread has been demonstrated in patients with
widespread metastases (DiPaola et al, 2006; Park et al, 2008).
However, the impressive antitumour activity of OVs seen in
experimental model systems has not translated into effective
‘cures’ in patients. This could at least in part be attributed to the
presence of a tumour vascular network that acts as a barrier for
viral egress into tumours (Breitbach et al, 2007). It was therefore
our hypothesis that therapies targeted towards the vasculature can
be exploited for the purpose of improving the systemic delivery of
OVs to tumours. To test this hypothesis, we investigated the
antitumour activity of OVV expressing the enhanced green
fluorescence protein (OVV-EGFP) in combination with photo-
dynamic therapy (PDT).
Photodynamic therapy is a clinically approved therapy for solid
tumours that is based on the photoactivation of a tumour-
localising agent, the sensitiser, resulting in the generation
of cytotoxic singlet oxygen (
1O2) (Pandey et al, 1991). The
chlorin-based 2-[1-hexyloxyethyl-]-2-devinyl pyropheophorbide-a
(HPPH), is a second-generation sensitiser that exhibits favourable
photophysical and pharmacokinetic properties and is currently
being investigated in clinical trials (Bellnier et al, 2003). In
preclinical studies, HPPH-PDT has been shown to result in varying
patterns of vascular, cellular and inflammatory responses, and
long-term tumour control rates depending on the treatment
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Here, we examined the therapeutic activity of HPPH-sensitised
PDT in combination with thymidine kinase (TK)- and vaccinia
growth factor (VGF)-deleted vaccinia virus expressing the EGFP as
a tracking marker (Gil et al, 2009) against NXS2 neuroblastomas
established in syngeneic mice and human FaDu xenografts
established in athymic nude mice. The objectives of the study
were to determine whether HPPH-sensitised PDT enhances the
antitumour efficacy of OVV and elucidate the potential mechanism
of interaction between the two treatments.
MATERIALS AND METHODS
Cell lines and generation of EGFP expressing rOVV
The murine GD2 ganglioside
þ, NXS2 neuroblastoma cell line, was
provided by Dr RA Reisfeld (The Scripps Research Institute). FaDu
head and neck squamous cell carcinoma was provided by Dr YM
Rustum (RPCI), and human HuTK-143 fibroblasts were obtained
from ATCC (CRL-8303). The OVV-EGFP virus was generated by
homologous recombination using VSC20 vaccinia virus and the
vaccinia shuttle plasmid pSEL-EGFP (McCart et al, 2001) as
described previously (Gil et al, 2009). The VSC20 vaccinia virus
with lacZ gene cloned in place of the VGF gene was obtained from
Dr B Moss (National Institutes of Health) and the pSEL-EGFP
vaccinia shuttle plasmids were obtained from Dr D Bartlett
(University of Pittsburgh Cancer Institute). Multiple plaques of
the recombinant viruses were isolated in HuTK-143 cells by BrdU
selection. After amplification on HeLa cells, the OVV-EGFP virus
was purified over the sucrose gradient, titrated, and the expression
of EGFP in infected NXS2 and FaDu cells was confirmed by
immunofluorescence microscopy.
UV light inactivation of viruses was done as described (Guse
et al, 2010). Briefly, viruses were suspended in 10mgml
–1psoralen
in Hanks balanced salt solution containing 0.1% bovine serum
albumin and treated with UV light (365nm) for 3min. A plaque
assay was used to confirm lack of viral replication.
In vivo studies
Female A/J and nu/nu CByJ.Cg-Foxn1nu/J. mice (Jackson Labora-
tory, Bar Harbor, ME, USA) were inoculated s.c. on the right
shoulder with 2 10
6 NXS2 and 5 10
6 FaDu cells, respectively.
NXS2-bearing mice (n¼10–15) were injected i.v. with 10
8 plaque-
forming units (PFUs) of OVV-EGFP, whereas in FaDu-challenged
mice, the viral dose was reduced to 2.5 10
7 PFU. After 7 days, the
FaDu tumour-bearing nude mice received i.p. 100mg of neutralis-
ing antibodies (neutralizing titre 1:100) prepared from sera of
vaccinia virus-immunised mice to inhibit disseminated infection
associated with acute inflammatory response (Guse et al, 2010).
The neutralising antibodies were delivered for an additional 4
days. This treatment prevents the release of extracellular enveloped
vaccinia virus from infected cells (Vanderplasschen et al, 1997).
2-[1-Hexyloxyethyl-]-2-devinyl pyropheophorbide-a (0.45mmol
kg
–1) was injected i.v. and tumours were illuminated with 665-nm
wavelength light 24h later. The light source consisted of a dye laser
(Spectra-Physics, Newport Corporation, Irvine, CA, USA) pumped
by an argon ion laser tuned to 665nm using DCM dye (Exciton
Inc., Dayton, OH, USA). The PDT treatment was delivered using
three illumination regimens: 48Jcm
–2 delivered at 7mWcm
–2,
128Jcm
–2 at 14mWcm
–2 and 135Jcm
–2 at 75mWcm
–2. For
combination studies, OVV-EGFP was injected i.v. 12h after PDT.
Tumour-bearing mice treated with HPPH or OV served as
controls. Tumour growth was monitored by measuring s.c.
tumours once to three times a week with a microcaliper until they
reached a volume 1700mm
3, at which time the mice were
euthanised. Tumour volume, V, was calculated with the formula
V¼(lw
2/2), where l is the longest axis of the tumour and w is the
axis perpendicular to l. Log-transformation was applied to V for
purpose of statistical analysis. For the therapy of metastatic
disease, NXS2-bearing mice (n¼6) underwent PDT and/or OV,
and tumours (V¼B200mm
3) were excised 7 days later. Control
mice had the primary tumour excised without PDT/OVV-EGFP
treatment. Survival was defined as the point at which mice were
euthanised because of extensive tumour burden. All experimental
procedures were approved by the Institutional Animal Care and
Use Committee at the RPCI.
Mouse foot response assay
The mouse foot response assay was performed on non-tumour-
bearing A/J mice to assess normal tissue phototoxicity in vivo as
described previously (Pandey et al, 1991). Briefly, HPPH
(0.45mmolkg
–1) was administered i.v. alone or in combination
with OVV-EGFP (10
8 PFU, injected 12-h post PDT). The mice were
divided into four groups (three mice per group) to analyse skin
phototoxicity after exposure to light (similar to PDT conditions)
produced by the solar simulator (Model 6137, ORIEL Co., Irvine,
CA, USA) (Pandey et al, 1991). One of the hind feet of each mouse
in the first group was exposed to light (at the therapeutic dose) at
24h post HPPH injection. The subsequent groups were exposed at
48, 72 and 96h, respectively. In each group, the unexposed hind
feet served as controls. Foot response was judged using a 0–3
scale: 0–0.1¼no apparent difference from normal, 0.3¼slight
oedema, 0.5¼moderate oedema, 0.75¼large oedema, 1.0¼large
erythema with exudate, 1.2¼moderate oedema with slightly crusty
appearance, 1.5¼definite erythema, 1.65¼slightly damaged
and/or slight fusion of toes; 2.0¼most toes are fused but no
change in general shape. Response 42.0 indicates unacceptably
severe normal tissue reaction (Pandey et al, 1991).
Immunohistochemical and flow cytometry analyses
Paraffin sections (4-mm-thick) of tumours were stained by a
routine immunohistochemical method using a rat mAb specific for
CD31 (clone MEC 13.3; Pharmingen, San Diego, CA, USA) at 1:30
dilution in PBS for 60min at room temperature, followed by
biotinylated goat anti-rat IgG (Pharmingen) at 1:100 dilution for
30min, streptavidin-peroxidase (50–242; Zymed, San Francisco, CA,
USA) for 30min, and diaminobenzidine for 5min.
Numbers of neutrophils/MDSCs in NXS2 tumours and the
peripheral blood in tumour-bearing mice were determined by
staining with PE- and PECy7-conjugated mAbs to Gr1 and CD11b
(BD Pharmingen, San Diego, CA, USA), respectively. Before
specific Ab staining, cells were incubated with Fc blocker (anti-
CD16/CD32mAb) for 10min. Background staining was assessed
using isotype controls. All flow cytometric evaluations were
performed on a FACScan flow cytometer (Becton Dickinson,
Franklin Lakes, NY, USA).
Characterisation of reported gene expression and viral
replication
FaDu cells were incubated with or without 0.8mM. 2-[1-Hexyloxy-
ethyl-]-2-devinyl pyropheophorbide-a for 24h before light treat-
ment and infection with OVV-EGFP at multiplicity of infection
(MOI) of 5 PFU per cell. Expression of EGFP was determined 16h
after the treatment by flow cytometry. The viral titres were
determined by a plaque assay 72h later. To quantify intratumoural
load of OVV, tumours were resected 5 days after the OV and PDT
treatments, homogenised and analysed by a plaque assay.
Analysis of tumour perfusion
Tumour-bearing mice were injected intravenously with 100mlo fa
50% solution of 100nm diameter orange fluorescent microspheres
PDT in combination with oncolytic virotherapy
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euthanised and the tumours were immediately snap frozen as
previously described (Breitbach et al, 2007). Tumour perfusion
was analysed by visualising fluorescent microspheres in the
vasculature of fixed sections using a Zeiss Axiophot HRM Inverted
fluorescent microscope (Zeiss Inc., Jena, Germany) and analysed
using Image-Pro 6.2 software (Media Cybernetics Inc., Silver
Spring, MD, USA).
Magnetic resonance imaging
Experimental magnetic resonance imaging (MRI) examinations
were performed using a 4.7T/33-cm horizontal bore magnet
(GE NMR Instruments, Fremont, CA, USA) incorporating
AVANCE digital electronics (Bruker Biospec, Paravision 3.0.2,
Bruker Medical, Billerica, MA, USA). Blood volume and perme-
ability measurements were estimated from T1-weighted contrast-
enhanced MRI (CE-MRI) acquisitions performed using the
intravascular contrast agent, albumin-GdDTPA (Contrast Media
Laboratory, University of California, San Francisco, CA, USA), as
described previously (Seshadri et al, 2008). The agent contains 35
GdDTPA molecules (94.3mM) that were bound to each human
serum albumin (2.69mM). Anatomic coverage included the
tumour, kidneys, vena cava and murine muscle tissue. A series
of three preliminary noncontrast enhanced images, with repetition
times (TR) ranging from 360 to 6000ms, was acquired before an
intravenous bolus injection of the contrast agent for the
determination of regional precontrast T1 relaxation values.
Following these baseline acquisitions, albumin-GdDTPA
(0.1mmolkg
–1) was administered through tail vein injection,
and a second series of five postcontrast images was serially
obtained for B45min (day 1). T1 relaxation rates were determined
using a saturation recovery, fast spin echo sequence with an
effective echo time (TE) of 10ms, and a TR ranging from 360 to
6000ms (FOV¼32 32mm, slice thickness¼1.0mm, matrix
size¼128 96 pixels, number of excitations (NEX)¼3). Following
image acquisition, animals were treated with PDT and 12h later,
the imaging protocol was repeated. Raw image sets were
transferred to a processing workstation and converted into Analyze
format (Analyze 7.0, Analyze Direct, Overland Park, KS, USA). Blood
volume and permeability maps were calculated on a pixel-by-pixel
basis using MATLAB (Mathworks Inc., Natick, MA, USA).
Statistical analysis
The statistical significance of the difference between groups was
performed using the two-tailed Student’s t-test assuming equal
variance. Mixed model analysis of variance was used to compare
viral titres in tumours treated with virotherapy or PDT and
virotherapy. Po0.05 was considered statistically significant. The
P-values for the pairwise group comparisons for the average
tumour growth were computed using a repeated measure ANOVA.
Kaplan–Meier survival plots were prepared and median survival
times were determined for tumour-challenged groups of mice.
Statistical differences in the survival across groups were assessed
using the log rank Mantel–Cox method. Data were presented as
arithmetic mean±s.d., and analysed using JMP (SAS Institute Inc.,
Cary, NC, USA) on a Windows-based platform.
RESULTS
PDT in combination with OV inhibits primary tumour
growth
Two groups of NXS2-bearing A/J mice with tumour volumes
ranging from 100 to 200mm
3 and 200 to 300mm
3 were subjected
to treatments with PDT using three different illumination regimens
determined by fluence and fluence rates: 48Jcm
–2 delivered at
7mWcm
–2, 128Jcm
–2 at 14mWcm
–2 and 135Jcm
–2 at
75mWcm
–2 (Figures 1A and C) alone or in combination with
OVV-EGFP (Figures 1B and D). The virus was injected i.v. 12h
after PDT since delivery of the virus before PDT treatment led to
viral inactivation (data not shown). Additional groups of tumour-
bearing mice that were treated with HPPH sensitiser without
illumination or OVV-EGFP virus alone served as controls. As
shown in Figures 1A and C, PDT using the high fluence/low fluence
rate regimen (128Jcm
–2,1 4 m W c m
–2) exhibited the highest
antitumour efficacy in both groups of mice and delayed
progressive growth of the tumour already 2 weeks after the
treatment (Po0.01). The other PDT regimens consisting of a low
fluence 48Jcm
–2 delivered at 7mWcm
–2 fluence rate and a high
fluence 135Jcm
–2 delivered at 75mWcm
–2 fluence rate were less
effective in inhibiting tumour growth. Tumour-free mice were not
detected in any of the PDT-treated groups.
Similar to the antitumour effects of PDT treatments, systemic
administration of OVV-EGFP only delayed tumour progression
compared with control mice (Figures 1A–D; P¼0.021). In
contrast, 50% (5 out of 10) of mice with small tumours
(V¼100–200mm
3) treated with the combination of PDT
(128Jcm
–2at 14mWcm
–2) and OV showed complete and durable
tumour regression (Figure 1B, denoted as combo 2; Po0.001). This
combination treatment also inhibited growth of larger tumours
(V¼200–300mm
3), although complete tumour eradication was
only observed in 20% of animals (Figure 1D). Other illumination
regimens (48Jcm
–2 delivered at 7mWcm
–2 and 135Jcm
–2 at
75mWcm
–2) used alone (Figures 1A and C) or in combination
with OVV-EGFP (Figures 1B and D; denoted as combos 1 and 3,
respectively) also exhibited higher antitumour effects compared
with the respective monotherapy treatments but were less effective
than the combination of the optimally curative PDT regimen
(128Jcm
–2,1 4m Wc m
–2) and OV.
We then investigated whether PDT treatment (128Jcm
–2
delivered at 14mWcm
–2) enhances the antitumour efficacy of
OVV-EGFP treatment against human xenografts in athymic nude
mice. For these studies, human FaDu cell carcinoma xenografts
were utilised since multi-institutional phase II–III clinical trials
evaluating PDT of head and neck tumours have demonstrated
the efficacy of this minimally invasive therapy against early
oropharyngeal primary and recurrent cancers (Biel, 2006). In the
initial experiments, nude mice with s.c. FaDu tumours
(V¼220±45mm
3) were treated with single therapy and analysed
for inhibition of tumour growth. Figure 2A shows that PDT
(128Jcm
–2 at 14mWcm
–2) monotherapy resulted in 60%
tumour-free survival (P¼0.002), whereas treatment with OV
caused 25% tumour-free animals (P¼0.005). On the other hand,
the combined 128Jcm
–2 at 14mWcm
–2 and OV treatments
increased the survival rate to 92% (Po0.001), and was most
effective when the virus was delivered 12h after PDT (Figure 2B).
Administration of the virus 4 or 24h after PDT resulted in o80%
tumour-free survival, whereas delivery of the virus immediately
after the illumination regimen was not beneficial (Figure 2B). To
determine the effect of different illumination regimens on survival
rates of FaDu, we performed additional experiments using
48Jcm
–2 at 7mWcm
–2 or 135Jcm
–2 at 75mWcm
–2 followed
by OVV-EGFP delivered 12h later. Consistent with the results
obtained using NXS2 tumour, PDT treatments consisting of a low
fluence 48Jcm
–2 delivered at 7mWcm
–2 fluence rate and a high
fluence 135Jcm
–2 delivered at 75mWcm
–2 fluence rate used in
combination with OVV were less effective, resulting in 60% and
40% tumour-free survival rates, respectively (Figure 2C).
Contrast enhanced-MRI of tumour perfusion after PDT
reveals vascular disruption at the time of virus
administration
To investigate the potential mechanisms of interaction between
PDT and oncolytic virotherapy, we examined the effect of the PDT
PDT in combination with oncolytic virotherapy
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delivery. Non-invasive CE-MRI with albumin-GdDTPA was
performed to assess the vascular response of FaDu
(V¼100.8±30.8mm
3) to PDT (128Jcm
–2 at 14mWcm
–2)1 2 h
after the treatment. Concentration of a contrast agent within the
tumour was estimated by measuring the change in T1-relaxation
rate (DR1) in the tumour. Individual R1 maps (R¼1/T1) along
with blood volume and permeability maps were generated on a
pixel-by-pixel basis at baseline and post-treatment time points. As
shown in Figure 3A, FaDu tumours (bounding box) exhibited
regions of high blood volume before PDT (pre-PDT) indicating the
presence of a functioning tumour vascular network. A spatially
heterogenous distribution of regions with enhanced permeability
was also observed. At 12-h post PDT, tumours were characterised
by central regions of low blood volume along with markedly
hyper-permeable regions in the tumour periphery (Figure 3A,
overlay). Consistent with this observation, the change in
T1-relaxation (DR1) values calculated from regions-of-interest
placed in the tumour centre showed a statistically significant
(Po0.05) reduction 12-h post PDT (0.027±0.01) compared with
baseline (0.369±0.06). In contrast, estimates of contrast agent
concentration in the peripheral regions of the tumours did not
reveal significant differences between baseline (0.316±0.05) and
post-treatment (0.287±0.10) time points. The OVV had no effect
on tumour vasculature during the first 12h following the virus
delivery (not shown).
PDT enhances intratumoural viral titres
The results of CE-MRI performed 12h after PDT treatment
suggested that blood vessels in tumour periphery that survived the
illumination regimen of 128Jcm
–2 at 14mWcm
–2 could serve as
effective conduits for delivery and spread of OVV-EGFP within the
tumour microenvironment. To assess the effect of the optimally
curative PDT treatment on intratumoural viral loads and compare
it with that of other illumination regimens (48Jcm
–2at 7mWcm
–2
and 135Jcm
–2 at 75mWcm
–2), tumours were resected 5 days
after the treatment and viral titres were quantified by a standard
plaque assay. For the analysis, we used the FaDu tumour model
system, which is highly susceptible to OVV-EGFP infection.
Figure 3B revealed over 10-fold higher viral titres recovered from
tumours after the combined 128Jcm
–2 at 14mWcm
–2 and OV
treatment compared with control tumours (P¼0.004). Only small
increases in viral titres were measured in tumours treated with
NXS2 tumour size 100–200mm3
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Figure 1 Inhibition of primary NXS2 tumours with PDT and OVV-EGFP. Tumour-bearing mice (n¼10–15) were enrolled when tumour size was
100–200mm
3 or 200–300mm
3 and randomised into two groups. (A and C) Mice were treated with HPPH-PDT of 48Jcm
–2at 7Wcm
–2, 128Jcm
–2at
14mWcm
–2 and 135Jcm
–2 at 75mWcm
–2. Control animals received HPPH. (B and D)1 0
8 PFU of OVV-EGFP was delivered i.v. alone or 12h after
PDT. Data were plotted in log scale as mean±s.d., over treatment time. The P-values for the pairwise group comparisons for the average tumour growth
were computed using ANOVA (***Po0.001). Combo 1, denotes combination of PDT (48Jcm
–2at 7Wcm
–2) and OV; combo 2, denotes combination
of PDT (128Jcm
–2 at 14mWcm
–2) and OV; and combo 3, denotes combination of PDT (135Jcm
–2 at 75mWcm
–2) and OV.
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–2 at 75mWcm
–2 and 48Jcm
–2 at
7mWcm
–2. The differences in intratumoural viral titres after
PDT treatments were also reflected in numbers of EGFP
þ cells
measured by imaging cytometry on single cell suspensions
(Figure 3C). The analyses revealed significantly higher numbers
of OVV-EGFP-infected cells after treatment with the 128Jcm
–2at
14mWcm
–2 illumination regimen compared with the untreated
controls (68.0±15% vs 12.0±5.3%, respectively; Po0.001). It is
noteworthy that EGFP expression in FaDu tumours after PDT of
128Jcm
–2 at 14mWcm
–2 was elevated compared with the
untreated counterparts although the differences did not reach
statistical significance (57793±7654 and 51086±3443,
respectively; P¼0.07). This could reflect an effect of PDT-induced
inflammatory responses characterised by low levels of IL-6
cytokine and MIP-1 and MIP-2 chemokine expression (Henderson
et al, 2004), and was consistent with an enhanced activity of the
synthetic early/late viral promoter stimulated by factors activated
or released from tumour after PDT treatment (Kick et al, 1995;
Wild et al, 2005; Mitra et al, 2006). However, it is also possible that
the HPPH sensitiser could affect the viral promoter activity and/or
viral replication in tumour cells.
Tumour cells after PDT treatment are susceptible to
OVV-EGFP infection
We next investigated the effect of the optimally curative PDT
regimen on the activity of the synthetic early/late promoter and
viral replication in vitro. FaDu cells were cultured for 24h in the
presence or absence of HPPH before infection with OVV-EGFP
(MOI of 5 PFU per cells). Tumour cells that were treated with light
(identical to the PDT condition) or PDT were also included in the
study. The expression of EGFP determined 16h after the viral
infection by a flow cytometry analysis revealed that HPPH or light
treatment applied separately had small effects on the synthetic
early/late promoter activity (Figure 4A). Similarly, no changes in
viral titres were detected in cell cultures 72h after the treatment
(Figure 4B). On the other hand, PDT-treated FaDu cells exhibited
profound decreases in the promoter activity (P¼0.008) as well as
viral replication (P¼0.011), although the cells were capable of
generating a replication competent virus.
OV treatment does not increase normal tissue
phototoxicity
The effects of OV treatment on normal tissue phototoxicity was
examined using the mouse foot response assay. As shown in
Figure 4C, injection of OVV to HPPH-treated mice did not result in
any additional damage to normal mouse foot tissue after exposure
to light (Figure 4C). Only a moderate degree of oedema (score:
B0.7) was observed in both HPPH and HPPH-OV-treated mice on
day 1 at 24-h post injection of HPPH. Resolution of normal tissue
damage was observed within 3 days of treatment.
Vascular collapse in tumours after PDT and OVV
treatments
Previous studies have shown that oncolytic vesicular stomatitis
virus (VSV) and OVV cause vascular collapse within tumours 24h
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Figure 2 Therapeutic benefits of combination therapy against FaDu xenografts in nude mice. (A) Nude mice with s.c. FaDu tumours (n¼10–15;
V¼220±45mm
3) were injected with OVV-EGFP (2.5 10
7 PFU) or treated with PDT (128Jcm
–2 at 14mWcm
–2). Control mice received HPPH.
(B) FaDu-bearing mice were treated with PDT, and OVV-EGFP was delivered at time 0 or 4, 12 or 24h after PDT. (C) FaDu-bearing mice were treated
with 48Jcm
–2 at 7Wcm
–2 or 135Jcm
–2 at 75mWcm
–2 regimen followed by OVV-EGFP delivered 12h later. **Po0.01, ***Po0.001.
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sand 5 days after the respective infection (Breitbach et al, 2007,
2011). These findings raise a possibility that PDT-mediated
vascular destabilisation at the time of viral injection could be
further potentiated by OVV-EGFP. Therefore, we analysed changes
in tumour perfusion in a highly metastatic NXS2 tumour model 5
days after the mono- and combined-therapy treatments. In order
to visualise perfusion, 100nm fluorescence beads (microspheres)
were injected i.v. to tumour-bearing mice 5min before tumour
resection as described (Breitbach et al, 2007, 2011). Tumour
sections were prepared and analysed under fluorescence micro-
scopy. Figure 5A reveals a relatively uniform distribution of
fluorescence beads in the control tumours. The beads were
accumulated in the periphery of tumours treated with OVV-EGFP
or PDT monotherapy, and were detectable only in the tumour rim
after the combined treatment. The results of tumour perfusion
studies were consistent with immunohistochemical analyses of
tumour tissues stained with mAb directed to CD31 to visualise
blood vessels. Figure 5B shows that in tumour sections from
control mice, vascular endothelial cells were uniformly distributed
throughout the tumour. In contrast, tumours from mice treated
with the virus had substantially fewer blood vessels and these were
almost exclusively found in the tumour periphery. Following PDT,
vessels were largely disrupted, although few morphologically intact
endothelial cells could be identified consistent with the previous
findings (Henderson et al, 2004). After the combined PDT/OV
treatment, the viable vessels could not be accurately discerned as
they were largely necrotic both in the periphery and core of the
tumour.
Enhanced recruitment of neutrophils to tumours after
treatment with OV alone or in combination with PDT
It has been demonstrated that neutrophils are one of the first cell
type recruited to the sites of infections (Nathan, 2006), and have
been implicated in virus-induced loss of tumour perfusion by
clogging of small capillaries (Breitbach et al, 2011). On the basis of
these findings, and because Gr1
þCD11b
þ neutrophils/myeloid-
derived suppressor cells (MDSCs) have recently been involved in
regulating organ-specific tumour spread (Yan et al, 2010), we
investigated whether changes in tumour vasculature after PDT
and/or OV treatment would affect accumulation of neutrophils/
MDSCs in tumours and the peripheral blood of NXS2 tumour-
bearing mice. A double staining with Gr1- and CD11b-specific
mAbs followed by a flow cytometry analysis was carried out on
single cell suspensions prepared from tumours resected 5 days
after the treatment. A parallel analysis was performed on
peripheral blood collected from tumour-bearing mice at the time
of tumour resection. As shown in Figure 6A, there was
approximately two-fold higher accumulation of Gr1
þCD11b
þ
cells in the OVV-treated tumours (P¼0.005). The increased
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Figure 3 Photodynamic therapy-induced vascular disruption augments intratumoural viral replication. (A) Blood volume and permeability maps of mice
with FaDu tumours (n¼3) before and 12h after PDT (128Jcm
–2at 14mWcm
–2). Blood volume (pseudo-colourized in red) and permeability (pseudo-
colourized in green) maps were calculated from serial T1-weighted MR acquisitions performed before and after administration of albumin-GdDTPA.
Representative maps of a mouse bearing FaDu tumour (bounding box) are presented. (B) Intratumoural replication of OVV-EGFP in FaDu tumours. Nude
mice (n¼3) bearing FaDu tumours (200–300mm
3) were injected i.v. with OVV-EGFP (2.5 10
7 PFU). In some animals, the virus was delivered 12h after
the indicated PDT regimens. After 5 days, tumours were resected, homogenised, and a standard plaque assay was performed. The vaccinia titres are
presented as the mean log10±s.d. (error bars) of PFU per mg total protein of tumour tissues. **Po0.01. (C) The numbers of EGFP
þ tumour cells in the
same groups of mice were determined by multispectral image cytometry. Data are presented as arithmetic mean±s.d. of three independent experiments.
***Po0.001. The colour reproduction of this figure is available at the British Journal of Cancer online.
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saccumulation of the inflammatory cells in tumours coincided their
reduction in the peripheral blood (Figure 6A; P¼0.008). Similar
distributions of neutrophils/MDSC in tumours and blood were
observed in tumour-bearing mice after PDT and OV treatments
(Figure 6A; Po0.05). Altogether, these findings support the
previous observation that the vascular changes mediated by OVs
within the tumour may act as a sink for activated neutrophils
(Breitbach et al, 2007, 2011). Consistent with the report that
minimal numbers of tumour infiltrating Gr1
þCD11b
þ cells were
detected using the optimally curative PDT regimen (Henderson
et al, 2004), accumulation of inflammatory neutrophils in tumours
and the peripheral blood after PDT treatment 128Jcm
2 at
14mWcm
–2 did not differ from controls (Figure 6A).
Inhibition of metastatic disease by a combined PDT and
OV therapy
The ability of NXS2 neuroblastoma to develop spontaneous
metastasis after excision of the primary tumour (Neal et al,
2004) provided a model for investigating whether the tumour
vascular shutdown and infiltration of neutrophils induced by
OVV-EGFP alone or in combination with PDT (128Jcm
–2,
14mWcm
–2) affect the kinetics of metastatic disease. A/J mice
bearing established s.c. NXS2 tumours (V¼B200mm
3) under-
went single or combined treatment and tumours were excised
7 days later. Control mice had the primary tumour excised without
treatment. As shown in Figure 6B, untreated mice succumbed to
metastatic disease within B40 days after resection of the primary
tumour. Photodynamic therapy or OV treatment alone delayed
progression of metastatic disease in all mice, and led to tumour-
free survival in 50% of animals (Figure 6B, Po0.05). Metastatic
lesions developed primarily in the brachial and axillary lymph
nodes, and were less frequent in liver, spleen and bone marrow as
determined by staining with NXS2-reacting 14G2a mAb or tyrosine
hydroxylase-specific RT–PCR (Gil et al, 2009). On the other hand,
mice that received combined PDT (128Jcm
–2at 14mWcm
–2) and
OV treatment did not develop metastatic disease by day 50, and
only one out of six mice had recurrent tumour (P¼0.007). In
summary, the increased survival rate among NXS2 tumour-bearing
mice after the combined PDT regimen of 128Jcm
–2at 14mWcm
–2
and OV suggests that increases in inratumoural viral replication
together with a profound reduction in tumour perfusion associated
with the sink effect of activated neutrophils/MDSCs could prevent
destabilisation of a premetastatic niche leading to inhibition of the
metastatic spread.
DISCUSSION
Over the years, PDT has been clinically effective as a curative
(Rigual et al, 2009) and palliative treatment (Lightdale et al, 1995)
for solid tumours. Here, we report, for the first time, the use of
PDT to increase the antitumour efficacy of OV.
Engineered OVVs have demonstrated promising results in the
treatment of cancer in preclinical models and early clinical trials
(Park et al, 2008; Kirn and Thorne, 2009), and it is likely that OV
will be combined with other treatments to maximize their
effectiveness. Recent reports have demonstrated augmentation of
antitumour efficacy of OV by manipulating vascular endothelial
growth factor-mediated signalling (Guse et al, 2010; Kottke
et al, 2010). In contrast, our approach involved disruption of
tumour vasculature using PDT to enhance viral delivery and
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Figure 4 The effect of PDT on activity of the synthetic early/late promoter, viral replication, and normal tissue phototoxicity. (A) FaDu cells were
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sdistribution. The results show increased therapeutic efficacy of
vaccinia virus against primary and metastatic tumours when used
in combination with PDT.
The effectiveness of PDT is influenced by multiple parameters
such as the type of sensitiser, its dose, the interval between
sensitiser injection and photoactivation, the incident light dose
(fluence) and light dose rate (fluence rate) (Henderson et al, 2004).
In our study, maximal antitumour efficacy was observed when the
virus was administered 12h following PDT and the therapeutic
benefit with combination treatment was influenced by the PDT
treatment regimen. This is not surprising since the relative
contributions of the tumour cellular, vascular and inflammatory
responses following PDT are strongly influenced by the choice of
illumination scheme or the PDT regimen (Henderson et al, 2004;
Seshadri et al, 2005). Results of our MRI studies provide evidence
of significant tumour vascular disruption (12-h post PDT) at the
time of virus administration. However, this destruction of vascular
architecture was not associated with a complete cessation of blood
flow within the tumour, suggesting that the PDT-mediated changes
in tumour vasculature could enable delivery of oncolytic viruses to
tumours resulting in infection/lysis of tumour cells that survived
PDT treatment. The changes in tumour vascular permeability
might be associated with subtle endothelial injury well below a
critical threshold required for complete vascular collapse and
shutdown of perfusion. This PDT-mediated vascular destabilisa-
tion could be further potentiated by infection with OV that triggers
vascular collapse and a loss of blood flow to the interior of the
tumour, causing induction of massive cellular death. Several
possibilities can be considered for the PDT fluence rate-dependent
differences in the antitumour efficacy of the virus. It is likely that
the PDT-induced photosensitisation caused endothelial cell
microtubule depolarisation and induced formation of actin stress
fibres. Changes in the endothelial cell integrity, which are
maintained by cytoskeletal components such as filament actin
Control OV
Control OV
128@14 128@14 + OV
128@14 128@14 + OV
Figure 5 Decreases in blood perfusion within tumours after OVV treatment alone or in combination with PDT. (A) A/J mice with NXS2 tumours were
treated with PDT (128Jcm
–2at 14mWcm
–2) and/or OVV-EGFP (10
8 PFU), perfused with fluorescent microspheres on day 5 after the viral injection, and
euthanised 5min later. Control tumours derived from mice treated with UV-inactivated OV and HPPH. Three tumours were tested, and data from
representative tumours are shown. Scale bars, 100mm. (B) Immunohistochemical assessment of the tumour vasculature after treatment with OVV-EGFP
and/or PDT (128Jcm
–2at 14mWcm
–2). Tumours were harvested on day 5 after treatment. Sections of tumours were stained for anti-CD31 antigen, and
representative images are shown. Scale bars, 100mm.
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sand microtubules would lead to the formation of intracellular gaps
and endothelial barrier dysfunction (Hobbs et al, 1998; Chen et al,
2006). This would have little influence on extravasation of small
molecules such as conjugates of albumin, which is about 67kDa
with a diameter of about 7nm (Chen et al, 2006) because tumour
vessels typically have larger interendothelial junctions than normal
blood vessels (Roberts and Palade, 1997). However, it could
significantly facilitate the extravasation of larger molecules, such as
2000-kDa dextran estimated to be about 100nm (Yuan et al, 2003)
or vaccinia virus estimated for 300nm (Lun et al, 2009), which are
otherwise difficult to transport across the endothelial barrier.
Taken together, the favourable interaction observed with the
PDT and OV combination treatment is likely related to effective
targeting of both vascular and cellular components of the tumour.
The finding that PDT-treated tumour cells are susceptible to viral
infection and replication, indicate that these cells can serve as a
source of infectious viral particles available for dissemination
throughout the tumour microenvironment. Thus, an effective
targeting of multiple components by the combination treatment
could explain its efficacy not only in the treatment of the primary
tumour, but most importantly, against spontaneous metastasis.
The latter effect could be associated with vascular shutdown in the
primary tumours that affected migration of the metastatic cells to
other organs after a neutrophil-dependent initiation of microclots
within tumour blood vessels (Breitbach et al, 2011). Our
observation of vascular collapse and infiltration of neutrophils/
MDSCs after treatment with OVV-EGFP is consistent with
previous studies in a murine model using VSV (Breitbach et al,
2007). In addition, a profound reduction in tumour perfusion was
also observed in some patients with advanced hepatocellular
carcinoma following treatment with an oncolytic poxvirus, JX-594
in early phase trials (Liu et al, 2008; Park et al, 2008), suggesting
that a better understanding of the direct and indirect mediators of
tumour lysis by the combined treatment will help to optimize
therapeutic protocols to achieve the best possible outcomes in
patients.
In conclusion, our study provides evidence for the safety and
efficacy of the combined PDT-OV treatment against murine
tumours and human tumour xenografts. By investigating early
events following vaccinia virus infection in tumours, we have
discovered a novel, targeted mechanism of tumour destruction,
requiring the optimal combination of virus infection and changes
in tumour vasculature. The evidence that the use of PDT at low
fluence rate significantly enhances antitumour efficacy directly by
destroying tumour cells and indirectly by augmenting viral load in
the tumour tissue, suggests that potential mechanisms of interac-
tion between the two treatment modalities should be considered
for further clinical development. It is clear that a better
understanding of the direct and indirect mediators of tumour
lysis by the combined treatment will help to optimize therapeutic
protocols to achieve the best possible outcomes in patients.
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